KERYX BIOPHARMACEUTICALS

1 Marina Park Dr Ste 1200, Boston, Massachusetts, United States

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

57.1%

Phase 2

21.4%

Phase 4

14.3%

Trial Status Distribution

Completed

71.4%

Suspended

7.1%

Terminated

14.3%

Withdrawn

7.1%

Clinical Trials

Trials sponsored by this organization (14)

Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Phase 3

Withdrawn

interventional

Jan 202536 participants

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Phase 3

Suspended

interventional

Jun 202245 participants

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

Phase 4

Completed

interventional

Aug 2017206 participants

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

Phase 3

Completed

interventional

Oct 2014234 participants

A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia

Phase 2

Completed

interventional

Apr 201432 participants

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Phase 2

Completed

interventional

Nov 2012149 participants

A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis

Phase 3

Completed

interventional

Aug 2012168 participants

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

Phase 3

Completed

interventional

Oct 2010441 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations